Paid Clinical Trials Louisville

Discover 598 paid clinical trials in Louisville, Kentucky. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 598

Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Louisville KY, Lexington KY, Cincinnati OH, Indianapolis INshow 269 more

Code:

NCT05095376

Conditions

Glioblastoma

Gliosarcoma

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Lomustine

Magnetic Resonance Imaging

Photon Beam Radiation Therapy

Questionnaire Administration

Temozolomide

Optimizing TreatmentOptimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

Recruiting

PHASE3

Sponsor:

HELP for NOWS Consortium

Location:

Louisville KY, Jeffersonville IN, Lexington KY, Edgewood KYshow 16 more

Code:

NCT05980260

Conditions

Neonatal Opiate Withdrawal Syndrome

Eligibility Criteria

Sex: All

Age: 1 - 48

Healthy Volunteers: Not accepted

Interventions

Symptom-based Dosing Approach

Scheduled Opioid Taper Approach

Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting

PHASE2

Sponsor:

Allogene Therapeutics

Location:

Louisville KY, Lexington KY, Cincinnati OH, Indianapolis INshow 33 more

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

PembrolizumabLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Louisville KY, Nashville TN, Paducah KY, Chicago ILshow 68 more

Code:

NCT03486873

Conditions

Solid Tumors

Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Standard of Care (SOC)

Lenvatinib

Olaparib

MK-4280

HLA TestingA Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting

Sponsor:

TScan Therapeutics, Inc.

Location:

Louisville KY, Nashville TN, Cleveland OH, Detroit MIshow 13 more

Code:

NCT05812027

Conditions

Head and Neck Cancer

Cervical Cancer

Non Small Cell Lung Cancer

Melanoma

Ovarian Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tumor and HLA Profiling

SBRT & PembrolizumabSBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Recruiting

PHASE2

Sponsor:

RTOG Foundation, Inc.

Location:

Louisville KY, Cincinnati OH, Columbus OH, Saint Louis MOshow 15 more

Code:

NCT03546582

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Stereotactic Body Radiation Therapy (SBRT)

Observational StudyNational Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Recruiting

Sponsor:

Children's Hospital Medical Center, Cincinnati

Location:

Louisville KY, Cincinnati OH, Indianapolis IN, Nashville TNshow 53 more

Code:

NCT02852031

Conditions

Hypoplastic Left Heart Syndrome (HLHS)

Eligibility Criteria

Sex: All

Age: 0 - 15

Healthy Volunteers: Not accepted

Interventions

Collaborative Learning Network

INBRX-106 & PembrolizumabINBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Recruiting

PHASE2

PHASE3

Sponsor:

Inhibrx Biosciences, Inc

Location:

Louisville KY, Saint Louis MO, Chicago IL, Detroit MIshow 18 more

Code:

NCT06295731

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

INBRX-106

Pembrolizumab

AvacopanA Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Recruiting

Sponsor:

Amgen

Location:

New Albany IN, Lexington KY, Miamisburg OH, Nashville TNshow 33 more

Code:

NCT06072482

Conditions

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Avacopan

Placebo

Standard of Care

Integrity Implant SystemIntegrity Implant System Post Market Clinical Follow-Up Study

Recruiting

Sponsor:

Anika Therapeutics, Inc.

Location:

Louisville KY, Fishers IN, Greenville SC, Germantown TNshow 3 more

Code:

NCT06741527

Conditions

Rotator Cuff Tears of the Shoulder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Integrity Implant System